Balanced product information
Evidence, limitations and safety — in one consistent format.
This page separates authorised uses from investigational or reported uses. It does not provide personal medical advice or dosing instructions.
Product name
Retatrutide (LY3437943)
Catalogue label details describe what is displayed; they do not independently verify composition, quality, batch release or UK marketing authorisation.
What is it?
Retatrutide is a synthetic peptide being studied as a single molecule that activates three hormone receptors: glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon receptors.
It remains a clinical-trial medicine. A catalogue strength or pen format does not make a retatrutide product an authorised medicine or establish its quality, identity or suitability for human use.
Intended / recognised uses
Authorised / recognised uses
- There are currently no authorised medical uses for retatrutide in the UK.
Reported / investigational uses
- It is being studied in controlled clinical trials for obesity, type 2 diabetes and related metabolic conditions.
- Trial findings must not be treated as approval, a treatment recommendation or evidence that an independently supplied product is equivalent to the trial medicine.
How it works
GLP-1 and GIP receptor activity can influence appetite, satiety, insulin release and glucagon signalling. Glucagon-receptor activity may also affect energy expenditure and liver metabolism.
The balance of these three actions, and their long-term clinical significance, is still being investigated.
Potential benefits / effects
- Phase 2 studies reported reductions in body weight and improvements in some metabolic measures in selected trial participants.
- The size and durability of any effect, who may benefit, and long-term outcomes remain under study; individual results cannot be predicted.
Potential benefit is not a guarantee of benefit for any individual.
Risks & warnings
- Long-term safety, cardiovascular outcomes and risks at different exposures are not yet fully established.
- Important concerns include severe gastrointestinal effects, dehydration, gallbladder problems and acute pancreatitis. Increased heart rate has also been observed in trials.
- An unregulated or falsely labelled product adds separate risks involving identity, concentration, contamination, sterility and storage.
Possible side effects
Commonly reported in trials
- Nausea, diarrhoea, vomiting and constipation.
- Reduced appetite and other gastrointestinal symptoms; these were often more frequent during dose escalation in trials.
Serious or urgent concerns
- Persistent severe abdominal pain may indicate pancreatitis and requires urgent medical assessment.
- Severe dehydration, serious allergic reaction, gallbladder symptoms or clinically significant low blood glucose may require urgent care.
- Reliable frequencies for an unauthorised retail presentation are not established.
Who should not use it / precautions
- It should not be used outside an appropriately authorised clinical trial or lawful specialist pathway.
- Pregnancy, planning pregnancy, breastfeeding, childhood or adolescence, previous pancreatitis, gallbladder disease, severe gastrointestinal disease and significant liver or kidney disease require particular caution and professional advice.
- People with diabetes or taking glucose-lowering medicines require clinical review because glucose levels can change.
Interactions
- Formal interaction data are incomplete.
- Insulin or sulfonylureas could increase the risk of hypoglycaemia if combined with an incretin-based medicine.
- Delayed gastric emptying may alter how quickly some oral medicines are absorbed; all medicines and supplements should be reviewed by a prescriber or pharmacist.
Regulatory / legal status
- Retatrutide has no UK marketing authorisation and should not be described as MHRA-approved or licensed.
- The MHRA has warned that products sold as retatrutide outside clinical trials are unauthorised and may pose serious health risks.
- The HELIX 40mg presentation shown in this catalogue has not been verified here as an authorised UK medicinal product.
Monitoring / professional supervision
- Clinical trials use eligibility screening, protocol-controlled administration and scheduled safety monitoring.
- Relevant assessment may include medical history, weight and metabolic measures, glucose control, hydration, gastrointestinal symptoms, heart rate and symptoms suggesting pancreatitis or gallbladder disease.
- This page does not provide a dosing or monitoring plan for an individual.
Evidence & sources
Sources are selected for regulatory status, recognised uses and material safety information. They do not validate the HELIX-labelled presentation.
- MHRA — No summer shortcut for safe weight loss (retatrutide warning)
- New England Journal of Medicine / PubMed — Retatrutide for obesity, phase 2 trial
- ClinicalTrials.gov — Retatrutide phase 2 study NCT04881760
- MHRA — Strengthened warnings on acute pancreatitis with GLP-1 medicines
Sources accessed and content reviewed 12 September 2026. Regulatory status can change; consult the current official record.
Information disclaimer
HELIX — FOR INFORMATION ONLY. NOT FOR SALE.
The products displayed on this website are presented strictly for informational and educational purposes, helping visitors understand their descriptions, features and specifications. No products are offered for sale through this website, and no product orders or payments are accepted through this platform.
The information on this website does not constitute medical advice, a prescription or a recommendation to use any product. Displaying a product does not establish its regulatory approval, safety or suitability for an individual. Please consult an appropriately qualified healthcare professional for personal medical advice.
For a UK-facing website, this disclaimer does not by itself establish legal compliance. Public advertising of prescription-only medicines and advertising of unlicensed medicines are subject to legal restrictions; the catalogue, wording and presentation require appropriate regulatory review.
Licensed-provider information
Where permitted by applicable law, HELIX may display contact details for independent third-party providers whose registration details have been checked against an appropriate official register. Visitors may contact a listed provider directly to enquire about lawful availability and eligibility requirements.
Any supply is subject to the provider’s assessment, applicable regulations, and verification of all required documentation, which may include a valid prescription, professional licence, identification or other authorisation. A referral does not guarantee availability, eligibility or supply.
Registration status can change. Review the provider's regulator, registration number, official-register record and last-checked date, then verify the current status independently before engaging.